Aditya Bagrodia

So you decided looking at essentially oncologic outcomes, quality of life outcomes in patients considering focal therapy was going to be the way that you go. Fair. And maybe one other question before, you know, this is something I kind of struggle with. It's like, do you provide a skeleton to keep the conversation moving? Or do you kind of leave it open ended with all the opinions?

And many times, there's so many opinions that you never make any progress. Can you talk a little bit about that balance?

And many times, there's so many opinions that you never make any progress. Can you talk a little bit about that balance?

And many times, there's so many opinions that you never make any progress. Can you talk a little bit about that balance?

Yeah. I mean, I was exposed to this where patients receiving prostatectomy, for instance, and I'm sure we'll talk about this, would basically, to over-summarize, sign a bit of a global consent for interventions that we would consider non-major, if you will. And that's clearly where some...

Yeah. I mean, I was exposed to this where patients receiving prostatectomy, for instance, and I'm sure we'll talk about this, would basically, to over-summarize, sign a bit of a global consent for interventions that we would consider non-major, if you will. And that's clearly where some...

Yeah. I mean, I was exposed to this where patients receiving prostatectomy, for instance, and I'm sure we'll talk about this, would basically, to over-summarize, sign a bit of a global consent for interventions that we would consider non-major, if you will. And that's clearly where some...

interpretive latitude is allowed and then they'd get their procedure and maybe they'd have their prostatectomy extracted via vertical incision or horizontal incision maybe they'd have a certain type of lymphadenectomy maybe you know some of the newer things ish coming through the pipe

interpretive latitude is allowed and then they'd get their procedure and maybe they'd have their prostatectomy extracted via vertical incision or horizontal incision maybe they'd have a certain type of lymphadenectomy maybe you know some of the newer things ish coming through the pipe

interpretive latitude is allowed and then they'd get their procedure and maybe they'd have their prostatectomy extracted via vertical incision or horizontal incision maybe they'd have a certain type of lymphadenectomy maybe you know some of the newer things ish coming through the pipe

Retzius sparing versus traditional posterior approach or anterior approach or hood sparing, you know, God knows what that is well within your right as a surgeon to try to offer the best oncologic and functional outcome. Now they've been properly studied.

Retzius sparing versus traditional posterior approach or anterior approach or hood sparing, you know, God knows what that is well within your right as a surgeon to try to offer the best oncologic and functional outcome. Now they've been properly studied.

Retzius sparing versus traditional posterior approach or anterior approach or hood sparing, you know, God knows what that is well within your right as a surgeon to try to offer the best oncologic and functional outcome. Now they've been properly studied.

So maybe I'll ask, you know, when you're thinking about this, if I've got it right, how do you kind of decide what is a reasonable shade of gray versus this is really something beyond a typical modification within a standard that needs separate consent, infrastructure costs, et cetera, that you're kind of alluding to?

So maybe I'll ask, you know, when you're thinking about this, if I've got it right, how do you kind of decide what is a reasonable shade of gray versus this is really something beyond a typical modification within a standard that needs separate consent, infrastructure costs, et cetera, that you're kind of alluding to?

So maybe I'll ask, you know, when you're thinking about this, if I've got it right, how do you kind of decide what is a reasonable shade of gray versus this is really something beyond a typical modification within a standard that needs separate consent, infrastructure costs, et cetera, that you're kind of alluding to?

Yeah, I love that. I mean, you know, to maybe exaggerate a little bit. And if we took that same study and did it kind of through a more typical mechanism, let's just say the patient's been decided they need a prostatectomy and you have to get all these tests, audiometry and liver function chemistries and whatever. Then you get randomized.

Yeah, I love that. I mean, you know, to maybe exaggerate a little bit. And if we took that same study and did it kind of through a more typical mechanism, let's just say the patient's been decided they need a prostatectomy and you have to get all these tests, audiometry and liver function chemistries and whatever. Then you get randomized.

Yeah, I love that. I mean, you know, to maybe exaggerate a little bit. And if we took that same study and did it kind of through a more typical mechanism, let's just say the patient's been decided they need a prostatectomy and you have to get all these tests, audiometry and liver function chemistries and whatever. Then you get randomized.

Then you have research assistants that support these trials for three years. You have kind of all this stuff, this clutter, if you will, baked in, which makes it onerous to the research staff. The cost can become prohibitive immediately. And you end up saying, is it worth spending $2 million to try to answer this question? Not only is it worth, can I get somebody to pay that?